342013-81-4

Usage

Uses

Used in Pharmaceutical Industry:
(5-BROMOPYRIDIN-3-YL)-MORPHOLIN-4-YL-METHANONE is used as a potential candidate in drug development for its unique structural features, which may contribute to the creation of new medications or therapeutic agents.
Used in Organic Synthesis:
(5-BROMOPYRIDIN-3-YL)-MORPHOLIN-4-YL-METHANONE is used as a valuable building block in organic synthesis, allowing chemists to construct more complex molecules and chemical structures, potentially leading to advancements in various chemical and material applications.
Further research and analysis are required to fully explore the potential uses and properties of this chemical compound, ensuring its safe and effective application in relevant industries.

Upstream product

• 110-91-8 morpholine 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 39620-02-5 5-bromonicotinoyl chloride 

Downstream Products

• 113118-81-3 5-bromopyridine-3-carbaldehyde 
• 364793-91-9 4-((5-bromopyridin-3-yl)methyl)morpholine 
• 919347-16-3 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine 

Relevant academic research and scientific papers

OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS

A compound of Formula I : (I) or a pharmaceutically acceptable salt thereof, wherein: each R' is QR1; each Q is independently selected from a bond, -C1-C10 alkylene, -C2-C10 alkenylene, -C(O)-, -C(O)O-, -C(O)N(R1)-, -C(O)N(R1)SO2- -N(R1)C(O)-, - N(R1)-, -N(SO2(R1)), -N(R1)SO2- -C(O)NR4R5-, -N(R4R5)C(O)-, -N(R4R5)- - S-, -SO-, -SO2-, -S(O)O-, -SO2N(R1)- and -O-; each R1 is independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C1-C10 heteroalkyl, aryl, heteroaryl, C3-C10 cycloalkyl, -(C1-C10 alkylene)-C3-C10 cycloalkyl, halogen, cyano, C1-C10 alkylene- aryl, C1-C10 alkylene heteroaryl, C1-C10 heterocycloalkyl and -(C1-C10 alkylene)- C1-C10 heterocycloalkyl. The compounds are inhibitors of HDAC and therefore have potential utility in the therapy of a number of conditions including cancer and inflammation.

Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker

Forty-two compounds (series 8, 9 and 10) incorporated with diacylated piperazine have been synthesized and evaluated as novel Bcr-Abl inhibitors based on 'six-atom linker'. Five of them, 8d, 8h, 8l, 10m and 10p, displayed potent Bcr-Abl inhibitory activity comparable with Imatinib. Moreover, compounds 8e, 10q, 10s, and 10u were potent Bcr-Abl inhibitors with IC50 values at the sub-micromolecular level. Most compounds exhibited moderate to high antiproliferative activity against K562 cells. In particular, compound 9e was the most promising Bcr-Abl inhibitor. Docking studies revealed that the binding modes of these compounds were similar with Imatinib. These compounds could be considered as promising lead compounds for further optimization.

4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors

A series of 4-anilino-7-pyridyl-3-quinolinecarbonitriles was prepared as Src kinase inhibitors. A systematic SAR study of substitutions on both the pyridine ring and the 3-quinolinecarbonitrile core established the requirements for optimal activity. The l

METHOD FOR THE PRODUCTION OF NICOTINALDEHYDES

The invention relates to a method for producing nicotinaldehydes by reducing the corresponding nicotinic acid-morpholine amides.

3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors

This invention provides compounds of Formula (I), having the structure where T, Z, X, A, R1, R2a, R2b, R2c, R3, R4, and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.